Posted by Michael Wonder on 26 Apr 2021
Tagrisso recommended for approval in the EU by CHMP for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer
26 April 2021 - Opinion based on unprecedented results from the ADAURA Phase 3 trial where Tagrisso reduced the risk of disease recurrence or death by 80%.
AstraZeneca’s Tagrisso (osimertinib) has been recommended for marketing authorisation in the European Union for the adjuvant treatment of adult patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumour resection with curative intent.
